Fundraising news

AAV virus

Myotubular myopathy gene therapy trial to start in the UK

The US based company, Audentes Therapeutics, is currently developing a potential gene therapy (named AT132) for the treatment of X-linked myotubular myopathy (XLMTM).

Read more

In this section: Get involved

Keep in touch
- Enter Your Location -
- or -